This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Incyte's CEO Presents At Morgan Stanley Healthcare Conference (Transcript)

The two doses in the label are 15 milligrams and 20 milligrams twice a day, which were quite well for people who have platelet counts above 100,000 and we are challenging for people with platelet counts below 100,000. Because one of the major reversible side effects of using the drug are myelosuppression both decrease in platelet count and decrease in red count, although that latter is a somewhat transient phenomenon because there are recovery mechanisms that occur while you are still on the drug. So the platelet count early on can go down, it goes down below a certain level patients have to discontinue the drug.

And we have – since launched on a very nice study in low platelet count patients where we start them on a lower dose 5 milligrams twice a day and work up and we are finding that almost all of them can get to 10 milligrams BID and at that does they are getting essentially the same results on spleen reduction symptom relief that the less sick patients get at the higher doses and we put that in – we send that to the FDA for an update on the label and when requested we are obviously explaining that to physicians who might start a patient with low platelet count on the drug.

But as you might expect those patients were sick, much significantly sicker than the patients that we are currently seeing coming to the group of people who are now getting the drug and who we studied in Phase III. So some of them died, some of them can't tolerate the higher doses, so early on the discontinuation rate was higher. It seems to be modulating.

Read the rest of this transcript for free on

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs